Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 13/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 12/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4809086 | 0.99 | CYP3A4 (0.59) | CYP3A4CYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL1261240 | 0.89 | CYP3A4 (0.62) | CYP3A4CYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL14147690 | 0.88 | CYP3A4 (0.59) | CYP3A4CYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL1260727 | 0.88 | CYP3A4 (0.61) | CYP3A4CYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL13006977 | 0.86 | CYP3A4 (0.56) | CYP3A4CYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL13006958 | 0.83 | SCN9A (0.53) | CYP3A4CYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL13756750 | 0.83 | CYP3A4 (0.67) | CYP3A4CYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL4806227 | 0.83 | CYP3A4 (0.69) | CYP3A4CYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL14384308 | 0.83 | CYP3A4 (0.72) | CYP3A4CYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL12596869 | 0.82 | CYP3A4 (0.67) | CYP3A4CYP2C19CYP2C9CYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2335700-A1 | Hepatitis C virus polymerase inhibitors with a heterobicylic structure | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2011-06-22 | — | — | EP | disclosed |
| EP-2335700-A1 | Hepatitis C virus polymerase inhibitors with a heterobicylic structure | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2011-06-22 | — | — | EP | disclosed |
| US-7893084-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM CANADA LTD. (CA) | 2011-02-22 | — | — | US | disclosed |
| US-7893084-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM CANADA LTD. (CA) | 2011-02-22 | — | — | US | disclosed |
| US-7893084-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM CANADA LTD. (CA) | 2011-02-22 | — | — | US | disclosed |
| US-7803944-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-28 | — | — | US | disclosed |
| US-7803944-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-28 | — | — | US | disclosed |
| US-7803944-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-28 | — | — | US | disclosed |
| US-7576079-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2009-08-18 | — | — | US | disclosed |
| US-7576079-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2009-08-18 | — | — | US | disclosed |
| US-7157486-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2007-01-02 | — | — | US | disclosed |
| US-20060293306-A1 | Viral Polymerase Inhibitors | BEAULIEU PIERRE L | 2006-12-28 | — | — | US | disclosed |
| US-7141574-B2 | Series of fused heterocycle compounds having improved inhibitory activity against HCV polymerase; hepatitis treatment | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2006-11-28 | — | — | US | disclosed |
| US-20060160798-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2006-07-20 | — | — | US | disclosed |
| EP-1414441-A2 | HEPATITIS C VIRUS POLYMERASE INHIBITORS WITH HETEROBICYCLIC STRUCTURE | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-05-06 | — | — | EP | disclosed |
| EP-1414797-A2 | HEPATITIS C VIRUS POLYMERASE INHIBITORS WITH A HETEROBICYLIC STRUCTURE | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-05-06 | — | — | EP | disclosed |
| US-20040024190-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-02-05 | — | — | US | disclosed |
| US-20030176433-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-09-18 | — | — | US | disclosed |
| WO-2003010140-A2 | HEPATITIS C VIRUS POLYMERASE INHIBITORS WITH HETEROBICYCLIC STRUCTURE | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-02-06 | — | — | WO | disclosed |
| WO-2003010141-A2 | HEPATITIS C VIRUS POLYMERASE INHIBITORS WITH A HETEROBICYCLIC STRUCTURE | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176433-A1 | Viral polymerase inhibitors | NR4A1, RCOR1, RER1 | CYP3A4 482/4885CYP2C19 725/4885CYP2C9 1393/4885 |
| US-20060293306-A1 | Viral Polymerase Inhibitors | NR2C2, NR4A1, POLR2A | CYP3A4 430/4885CYP2C19 726/4885CYP2C9 1539/4885 |
| US-20060160798-A1 | Viral polymerase inhibitors | NR4A1, NR1I3, RER1 | CYP3A4 247/4885CYP2C19 839/4885CYP2C9 604/4885 |
| US-20040024190-A1 | Viral polymerase inhibitors | RCOR1, NR4A1, RER1 | CYP3A4 295/4885CYP2C19 456/4885CYP2C9 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.